Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | The case for local therapies alone in BCG-unresponsive NMBIC

Roger Li • 13 Feb 2025
GU Cancers 2025
Bladder Cancer Genitourinary Cancer

Roger Li, MD, H. Lee Moffitt Cancer Center, Tampa, FL, gives an overview of why local therapies alone are better than local and systemic treatments for BCG-unresponsive non-muscle invasive bladder cancer (NMBIC). Patient acceptance and tolerability concerns with systemic therapies make local therapies more sustainable, and Dr Li also highlights the effectiveness of intravesical delivery systems in treating the entire bladder. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Roger Li

Advancements and recent approvals in NMIBC: SunRISe-1, KEYNOTE-057, and more
1:07
Advancements and recent approvals in NMIBC: SunRISe-1, KEYNOTE-057, and more
Roger Li • 13 Feb 2025
Plasma ctDNA as a staging tool in upper tract urothelial carcinoma
2:45
Plasma ctDNA as a staging tool in upper tract urothelial carcinoma
Roger Li • 13 Feb 2025
Oncolytic virus therapy in early-stage bladder cancer w/ direct lesion contact via intravesical use
1:44
Oncolytic virus therapy in early-stage bladder cancer w/ direct lesion contact via intravesical use
Roger Li • 7 Nov 2024
T cell responses in responders vs. non-responders to oncolytic virotherapy in bladder cancer
1:44
T cell responses in responders vs. non-responders to oncolytic virotherapy in bladder cancer
Roger Li • 7 Nov 2024

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals